Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
METTL15P1 is a **pseudogene**, not an active protein-coding gene or therapeutic target. Pseudogenes are genomic DNA sequences similar to normal genes but typically nonfunctional; they do not produce active proteins because of disabling mutations, premature stop codons, or other genetic alterations. While some pseudogenes can be transcribed and occasionally have regulatory functions, there is no evidence that METTL15P1 encodes a functional methyltransferase or plays a role in disease processes or cellular pathways. As such, it is not considered a valid therapeutic target, nor are there any disease associations, interacting drugs, mechanisms of action, or safety concerns tied specifically to METTL15P1. This is likely a mistaken listing if you are searching for an active methyltransferase enzyme, as functional counterparts (such as METTL15 or METTL1) do exist, but METTL15P1 itself is not functionally relevant in drug discovery or clinical research. If you intended to refer to the **protein-coding gene METTL15** or any other member of the methyltransferase-like protein family, please specify, as these have recognized biological and disease roles[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methyltransferase like 15 pseudogene 1 (METTL15P1).